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Celiac Disease (CD, gluten induced enteropathy) is a relatively common severe
chronic gastrointestinal disease. believed to be present in up to 1% of Caucasians
in our population. The clinical features of CD include steatorrhoea, malnutrition,
failure to thrive which are also common features of Cystic Fibrosis (CF). The
coincidence of CF and CD have been reported previously, and one study based on
clinical and biochemical but not serological evaluation, followed by small bowel
biopsy (SBB) found CD conﬁrmed in 5 of 1100 CF patients. The advent of
serological screening tests, particularly tissue trans-glutaminase (tTG) has led to
increased ascertainment of CD, though the diagnosis should still be conﬁrmed SBB.
We report results from the ﬁrst survey of CF patients using modern serological
testing (tTG) and SBB. We screened 114 CF patients aged 1−18 yrs. attending the
CF clinic at BC Children’s Hospital in Vancouver. 7 patients had elevated tTG. Of
these, 5 were also +ve for HLADQ2 or DQ8. SBB in 4 was positive for CD, while
3 patients await SBB. A serological prevalence of 7% and conﬁrmed SBB diagnosis
of CD in 4% is greater than expected for the general population. Our results should
be conﬁrmed by other studies, but suggest that routine serological tTG screening
for CD is indicated in all CF patients.
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Introduction: In CF, liver disease is the third highest cause of death and gastroin-
testinal problems impact on quality of life. A designated CF Gastroenterology clinic
(CFGC) was established in 2001 to facilitate diagnosis and management. Families
are reviewed by a Gastroenterologist, a CF Dietitian and a CF Physician. We have
assessed the impact of this clinic on patient care.
Method: Retrospective case note review of patients attending the CFGC 2001–
2009.
Results: Forty three patients attended the clinic, 38/43 (20 male, 18 female) were
reviewed, 5 patient’s case notes were unavailable. The mean age at presentation
was 9.5 years (range 1−17). Reasons for referral: poor weight gain (13), abnormal
liver function tests (LFT’s) (10), abdominal pain (9), loose stools (5), vomiting
(5). Coeliac disease was excluded by serology in ﬁve patients and by biopsy in
nine. All patients with abnormal LFT’s were treated with ursodeoxycholic acid, 6
had portal hypertension and 3 were referred to UK liver centres. Eight patients
had clinical gastro-oesophageal reﬂux, 7/8 had endoscopy and/or contrast swallow,
all normal. Nine children had a percutaneous endoscopic gastrostomy tube for
nutritional supplementation.
Outcome: 31 patients were discharged to their usual CF care, 22/31 symptoms
improved, 9/31 diagnosed and given a plan of care. Two patients transferred to
adult services, 4 continue to attend the CFGC and 1 declined follow-up.
Conclusion: Attendance at the CFGC has resulted in a positive intervention in the
majority of patients. The clinic has been particularly helpful in supporting families
with the move to interventional feeding.
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The variable clinical manifestations of CF suggest the inﬂuence of modiﬁer
genes. Genetic and environmental factors that determine whether an individual
will develop associated complications are still being determined. Mutation analysis
is widely recommended for presymptomatic diagnosis of CF and HH (hereditary
hemochromatosis) the most frequent autosomal recessive diseases. Five C282Y
heterozygous carriers, fourteen H63D heterozygous carriers and one compound
heterozygous C282Y/H63D were identiﬁed out of 62 CF patients. We have analyzed
the phenotype of 20 (9 female, 11 male) CF patients HFE mutations carriers aged
from 2 to 25 years old. As the results showed the high frequency of HFE mutations
among patients with CF we have analyzed the frequency of C282Y and H63D
mutations in CF patients with different severity of CF manifestation. The obtained
results revealed no correlation between HFE gene mutations and severity of CF
manifestation, meconium ileus occurrence, gender and development of hepatobiliary
disturbances. HFE C282Y/H63D compound heterozygous patient, seven years old
boy, F508del homozygous had meconium ileus at the birth. The further studies of
a larger group of patients and monitoring them for long time will clarify the HFE
mutations inﬂuence on CF phenotype.
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The aim of study was to analyze the clinical and genetic characteristics of patients
with liver cirrhosis associated with cystic ﬁbrosis (CF). Liver cirrhosis was deﬁned
by ultrasonographic ﬁndings of distinct heterogeneity of liver parenchyma and
nodular liver surface and/or by liver biopsy ﬁndings. Portal hypertension was
suggested by enlarged spleen and abnormal portal venous ﬂow.
Ten patients with CF (nine males and one female) were found to have liver cirrhosis,
three of them with portal hypertension. Hepatic synthetic function was sufﬁciently
maintained in all of cirrhotic patients. Average age of patients with cirrhosis was
15.5 years (range 8−23). All patients had pancreatic insufﬁciency. Nutritional status
expressed as standard deviation score (Z) for weight (zW), for height (zH), for
weight for height (zW/H), and body mass index (BMI) showed these values:
zW=−0.73±0.98, zH=−0.65±0.45, zW/H=−0.05±0.59, and BMI = 18.86±2.36.
CF patients with liver cirrhosis tended to have milder pulmonary disease, with
mean FVC and FEV1 values of 96.5±9.6 and 92±14, respectively. Five of them
were with chronic Pseudomonas aeruginosa infection. Genetic analysis showed
higher frequency of F508del mutation in the group with cirrhosis (80%). The other
mutations found among these patients were: G542X, Y1092X and R1662.
In conclusion, liver cirrhosis associated with CF usually develops during the ﬁrst
decade. Patients with mail gender, pancreatic insufﬁcient and with severe CFTR
mutations are exposed to higher risk for developing liver cirrhosis. Liver cirrhosis
does not signiﬁcantly impact the pulmonary function and the nutritional status, until
the end-stage liver disease.
